Search research articles
Contact Us
Filters
Showing results (151-160 of 210) with videos related to
Page
of 21
Sort By:
The Journal of Allergy and Clinical Immunology
|
September 12, 2017
Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients
Aurélien Parpaleix, Laurent Boyer, Aurelie Wiedemann, et al.
Future Oncology (London, England)
|
March 12, 2019
I-O Optimise: a novel multinational real-world research platform in thoracic malignancies
Simon Ekman, Frank Griesinger, Paul Baas, et al.
The Lancet. Respiratory Medicine
|
November 1, 2024
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study
Hervé Léna, Laurent Greillier, Claire Cropet, et al.
BMC Cancer
|
April 1, 2014
A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer
Delphine Lerouge, Alain Rivière, Eric Dansin, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 11, 2015
Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study)
Denis Moro-Sibilot, Clarisse Audigier-Valette, Patrick Merle, et al.
Plos Currents
|
December 24, 2009
Modeling the critical care demand and antibiotics resources needed during the Fall 2009 wave of influenza A(H1N1) pandemic
Duygu Balcan, Vittoria Colizza, Andrew C Singer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 7, 2014
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer
Giorgio V Scagliotti, Enriqueta Felip, Benjamin Besse, et al.
Cancer Medicine
|
February 6, 2020
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study
Karim Amrane, Margaux Geier, Romain Corre, et al.
Respiratory Medicine and Research
|
October 29, 2025
Real-world management of unresectable stage III non-small-cell lung cancer: Impact of durvalumab consolidation therapy in French clinical practice
Christos Chouaid, Philippe Giraud, Marie Wislez, et al.
Journal of Cancer Research and Clinical Oncology
|
August 25, 2023
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
Hélène Doubre, Laurent Greillier, Grégoire Justeau, et al.
Page
of 21
Search research articles
Search
Showing results (151-160 of 210) with videos related to
Sort By:
Page
of 21
The Journal of Allergy and Clinical Immunology
|
September 12, 2017
Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients
Aurélien Parpaleix, Laurent Boyer, Aurelie Wiedemann, et al.
Future Oncology (London, England)
|
March 12, 2019
I-O Optimise: a novel multinational real-world research platform in thoracic malignancies
Simon Ekman, Frank Griesinger, Paul Baas, et al.
The Lancet. Respiratory Medicine
|
November 1, 2024
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study
Hervé Léna, Laurent Greillier, Claire Cropet, et al.
BMC Cancer
|
April 1, 2014
A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer
Delphine Lerouge, Alain Rivière, Eric Dansin, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 11, 2015
Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study)
Denis Moro-Sibilot, Clarisse Audigier-Valette, Patrick Merle, et al.
Plos Currents
|
December 24, 2009
Modeling the critical care demand and antibiotics resources needed during the Fall 2009 wave of influenza A(H1N1) pandemic
Duygu Balcan, Vittoria Colizza, Andrew C Singer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 7, 2014
An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer
Giorgio V Scagliotti, Enriqueta Felip, Benjamin Besse, et al.
Cancer Medicine
|
February 6, 2020
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study
Karim Amrane, Margaux Geier, Romain Corre, et al.
Respiratory Medicine and Research
|
October 29, 2025
Real-world management of unresectable stage III non-small-cell lung cancer: Impact of durvalumab consolidation therapy in French clinical practice
Christos Chouaid, Philippe Giraud, Marie Wislez, et al.
Journal of Cancer Research and Clinical Oncology
|
August 25, 2023
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
Hélène Doubre, Laurent Greillier, Grégoire Justeau, et al.
Page
of 21